Mineralys Therapeutics Inc (MLYS) - News Archive

Showing 9 of 9 results.

Breakthrough in Hypertension Treatment Mineralys Therapeutics Lorundrostat Shows Promising Results in Div...

Mineralys Therapeutics has unveiled pivotal data from their groundbreaking Phase 3 Launch-HTN trial, focusing on the novel aldosterone synthase inhibitor, lorundrostat. The presentation highlights significant achievemen...

Sep 5, 2025 • Major Pharmaceutical Preparations Industry Clinical Study Inc

Mineralys Therapeutics Reveals Promising Data for Lorundrostat at ESH 2025, Targets Future Engagements in Upcoming He...

Mineralys Therapeutics Unveils Groundbreaking Findings on Lorundrostat at ESH 2025 Amidst Conference Participation In a significant stride for hypertension treatment, Mineralys Therapeutics, Inc. (NASDAQ: MLYS) recently...

May 24, 2025 • Major Pharmaceutical Preparations Industry Product Service News Inc Inc Mineralys Therapeutics Mineralys Therapeut

Mineralys Therapeutics Sees Financial Boost with Successful Stock Offering; Whats Next for Investors

Mineralys Therapeutics, Inc. a biopharmaceutical company situated at the forefront of developing innovative therapies for hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA), has taken a signif...

Mar 18, 2025 • Major Pharmaceutical Preparations Industry Shares

Mineralys Therapeutics Set to Release Q2 2024 Financial Results and Host Conference Call on August 13, 2024 ...

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results RADNOR, Pa. Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments...

Aug 5, 2024 • Major Pharmaceutical Preparations Industry Announcement

Mineralys Therapeutics Propels Innovative Treatment for Hypertension and Chronic Kidney Disease with $120 Million Private Placement Financing.

Mineralys Therapeutics Secures $120 Million in Private Placement Financing, Advancing Promising Treatment for Hypertension and Chronic Kidney DiseaseRADNOR, Pa., Feb. 08, 2024 Mineralys Therapeutics, a clinical-stage bi...

Feb 8, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement

Revolutionizing Hypertension Treatment: Mineralys Therapeutics Initiates Pivotal Launch-HTN Trial for Lorundrostat, Topline Data Expected in 2H 2025

Mineralys Therapeutics, a leading pharmaceutical company, recently made an exciting announcement regarding the progress of their groundbreaking hypertension treatment, Lorundrostat. The company revealed that the first s...

Dec 21, 2023 • Major Pharmaceutical Preparations Industry Clinical Study

Decoding the Hypertension Enigma: Mineralys Therapeutics Links Obesity, Leptin, and Aldosterone in a Game-Changing Breakthrough, Paving the Path Towards Targeted Treatment with Lorundrostat

Mineralys Therapeutics Unveils Promising Findings on Lorundrostat s Targeted Approach to Tackle Uncontrolled Hypertension, Reinforcing the Link Between Obesity, Leptin, and AldosteroneNew Orleans, LA - In a groundbreaki...

Nov 11, 2023 Product Service News

Revolutionizing Treatment for Hypertension and Chronic Kidney Disease: Mineralys Therapeutics Steps Up to the Plate

Mineralys Therapeutics: Pioneering Breakthroughs in Hypertension and Chronic Kidney Disease TreatmentRADNOR, Pa., Nov. 09, 2023 - Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company s...

Nov 9, 2023 Product Service News

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

Late-breaking poster presentation at ASNs Kidney Week 2023 - - - Poster presentation at AHAs Scientific Sessions 2023Mineralys Therapeutics, a leading biopharmaceutical company focused on developing innovative therapies...

Oct 13, 2023 Earnings announcement